Amyloid precursor protein‐mediated mitochondrial regulation and Alzheimer's disease

Abstract

Despite clear evidence of a neuroprotective physiological role of amyloid precursor protein (APP) and its non‐amyloidogenic processing products, APP has been investigated mainly in animal and cellular models of amyloid pathology in the context of Alzheimer's disease. The rare familial mutations in APP and presenilin‐1/2, which sometimes drive increased amyloid β (Aβ) production, may have unduly influenced Alzheimer's disease research. APP and its cleavage products play important roles in cellular and mitochondrial metabolism, but many studies focus solely on Aβ. Mitochondrial bioenergetic metabolism is essential for neuronal function, maintenance and survival, and multiple reports indicate mitochondrial abnormalities in patients with Alzheimer's disease. In this review, we focus on mitochondrial abnormalities reported in sporadic Alzheimer's disease patients and the role of full‐length APP and its non‐amyloidogenic fragments, particularly soluble APPα, on mitochondrial bioenergetic metabolism. We do not review the plethora of animal and in vitro studies using mutant APP/presenilin constructs or experiments using exogenous Aβ. In doing so, we aim to invigorate research and discussion around non‐amyloidogenic APP processing products and the mechanisms linking mitochondria and complex neurodegenerative disorders such as sporadic Alzheimer's disease. Linked Articles This article is part of a themed section on Therapeutics for Dementia and Alzheimer's Disease: New Directions for Precision Medicine. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.18/issuetoc

The Role of Periodontitis and Periodontal Bacteria in the Onset and Progression of Alzheimer’s Disease: A Systematic Review

“…There are different hypotheses about the etiopathogenesis of Alzheimer's disease. The typical accepted hypothesis involves histopathologic alterations of senile plaques, neurofibrillary tangles, and neural cells caused by amyloid precipitation [41].…”

Therapeutics for dementia and Alzheimer's disease: New directions for precision medicine

“…Even though strategies to elevate expression or activity of these mechanisms still heavily rely on the amyloid cascade hypothesis, they do provide alternative therapeutic opportunities in dementia and relate to the overall increased interest in proteostatic clearance pathways that are further mentioned below. Better preclinically characterized tool compounds that modulate cellular Aβ and APP levels may also assist researchers such as Lopez Sanchez, van Wijngaarden, and Trounce () and Cecon et al (), providing insights into whether it is the loss of protective non‐amyloidogenic APP fragments or a gain of Aβ toxic function that is more detrimental in AD. Cellular location also appears to be an important factor in pathogenesis—the link between APP or APP‐derived peptides and mitochondrial metabolism remains unclear, despite the mitochondria being a location for APP and Aβ, and energy deficiency a recognized early event in AD progression (Lopez Sanchez et al, ).…”

“…Better preclinically characterized tool compounds that modulate cellular Aβ and APP levels may also assist researchers such as Lopez Sanchez, van Wijngaarden, and Trounce () and Cecon et al (), providing insights into whether it is the loss of protective non‐amyloidogenic APP fragments or a gain of Aβ toxic function that is more detrimental in AD. Cellular location also appears to be an important factor in pathogenesis—the link between APP or APP‐derived peptides and mitochondrial metabolism remains unclear, despite the mitochondria being a location for APP and Aβ, and energy deficiency a recognized early event in AD progression (Lopez Sanchez et al, ). Previously, the few dementia‐associated therapies aimed at mitochondrial dysfunction have focused on reversing oxidative stress and cell death pathways.…”

Rhodiola crenulata protects against Alzheimer's disease in rats: A brain lipidomics study by Fourier‐transform ion cyclotron resonance mass spectrometry coupled with high‐performance reversed‐phase liquid chromatography and hydrophilic interaction liquid chromatography

“…However, there is currently no drug that can reverse the mechanisms underlying AD. As most of these single‐targeted medicines are associated with various adverse side effects, it is of great significance to research and develop new drugs for the treatment of AD 6–9 …”